Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Sep 27, 2022 2:55pm
251 Views
Post# 34990149

RE:Lets Win Pancreatic cancer now following ONC

RE:Lets Win Pancreatic cancer now following ONC
https://letswinpc.org/promising-science/2022/09/21/aacr-conference-research-update/ -------------------------------------------------- 21 September, 2022 For the first time in two years, the 2022AACR Special Conference: Pancreatic Cancerwas held in person. The conference, held in Boston, attracted more than 600 physicians and scientists, all of whom have a special interest in advancing research on and treatment of one of the most formidable of foes. Without a doubt, progress has been made in understanding the basic biology of this heterogeneous disease. And in many cases, this research has led to better treatments that can extend the lives of some patients. Its also clear that more work needs to be done. ------------------------------------------------ Cheers!!!!!!!!!!!!!!!!!!!!!!
<< Previous
Bullboard Posts
Next >>